Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/16863
Title: Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Authors: Jiang, H
Zhang, W
Shang, P
Zhang, H
Fu, W
Ye, F
Zeng, T
Huang, H
Zhang, X
Sun, W
Sze, MYD
Yi, Q
Hou, J
Keywords: Adoptive immunotherapy
CD138 (syndecan-1)
Chimeric antigen receptor
Multiple myeloma
NK cells
Issue Date: 2014
Source: Molecular oncology, 2014, v. 8, no. 2, p. 297-310 How to cite?
Journal: Molecular Oncology 
Abstract: Reprogramming of NK cells with a chimeric antigen receptor (CAR) proved an effective strategy to increase NK cell reactivity and recognition specificity toward tumor cells. To enhance the cytotoxicity of NK cells against CD138-positive multiple myeloma (MM) cells, we generated genetically modified NK-92MI cells carrying a CAR that consists of an anti-CD138 single-chain variable fragment (scFv) fused to the CD3ζ chain as a signaling moiety. The genetic modification through a lentiviral vector did not affect the intrinsic cytolytic activity of NK-92MI toward human erythroleukemic cell line K562 cells or CD138-negative targets. However, these retargeted NK-92MI (NK-92MI-scFv) displayed markedly enhanced cytotoxicity against CD138-positive human MM cell lines (RPMI8226, U266 and NCI-H929) and primary MM cells at various effector-to-target ratios (E:T) as compared to the empty vector-transfected NK-92MI (NK-92MI-mock). In line with the enhanced cytotoxicity of NK-92MI-scFv, significant elevations in the secretion of granzyme B, interferon-γ and proportion of CD107a expression were also found in NK-92MI-scFv in response to CD138-positive targets compared with NK-92MI-mock. Most importantly, the enhancement in the cytotoxicity of NK-92MI-scFv did not attenuate with 10Gy-irradiation that sufficiently blocked cell proliferation. Moreover, the irradiated NK-92MI-scFv exerted definitely intensified anti-tumor activity toward CD138-positive MM cells than NK-92MI-mock in the xenograft NOD-SCID mouse model. This study provides the rationale and feasibility for adoptive immunotherapy with CD138-specific CAR-modified NK cells in CD138-positive plasmacytic malignancies, which potentially further improves remission quality and prolongs the remission duration of patients with MM after upfront chemotherapy.
URI: http://hdl.handle.net/10397/16863
ISSN: 1574-7891
DOI: 10.1016/j.molonc.2013.12.001
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

38
Last Week
0
Last month
3
Citations as of May 25, 2017

WEB OF SCIENCETM
Citations

33
Last Week
0
Last month
3
Citations as of May 22, 2017

Page view(s)

32
Last Week
4
Last month
Checked on May 28, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.